Bradykinin

Star0

DB12126InvestigationalSmall molecule

Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.

Formula / weight: C₅₀H₇₃N₁₅O₁₁ · 1060.2085 g/mol (avg)
Also known as: L-bradykinin
Code names: Bradykinin (synthetic) · BRS-640 · PRS 640

Resolves to

Compound

UNIIS8TIM42R2WCAS58-82-2ChEMBLCHEMBL406291ChEBI3165PubChem439201KEGGC00306

Clinical / RWD

PharmGKBPA166109574

Structure

InChIKeyQXZGBUJJYSLZLT-FDISYFBBSA-NSMILES

N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

Targets

P30411BDKRB2

What you can answer from here — as of September 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Drug interactionsStructured to mechanism, not free text

14Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Bradykinin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account